Could Hydroxychloroquine Be a Missing Piece in Long COVID Treatment?

Hydroxychloroquine (HCQ), a drug historically used to treat malaria and autoimmune conditions like systemic lupus erythematosus (SLE), gained attention early in the COVID-19 pandemic for its potential antiviral and immunomodulatory effects. While its role in acute COVID-19 management has been controversial, ongoing investigations explore its possible benefits in addressing long COVID—a complex, multisystem condition characterized by persistent symptoms such as fatigue, brain fog, and cardiovascular issues.

This article examines HCQ’s potential role in long COVID, considerations for its use, and the precautions necessary to ensure patient safety.

The Mechanisms Behind Hydroxychloroquine

HCQ has antiviral properties, reducing viral replication and dissemination by altering the pH within cells and interfering with viral entry. Additionally, it has immunomodulatory effects, dampening overactive immune responses that may contribute to inflammatory conditions. These properties are relevant in long COVID, where persistent inflammation and immune dysregulation are believed to play key roles.

Key Considerations for Hydroxychloroquine in Long COVID

While there is limited data on HCQ for long COVID, insights from its use in acute COVID-19 and SLE provide a foundation for cautious application:

1. Timing and Dosing:

  • Acute Treatment Approach: Early initiation of HCQ during viral replication phases may be most beneficial. A typical regimen includes a loading dose of 400 mg twice daily on the first day, followed by 200 mg twice daily for four days.

  • Long-Term Use: Long-term use for chronic symptoms requires additional study but should mirror protocols used in autoimmune conditions, where lower doses minimise risks.

2. Cardiac Monitoring:

  • HCQ has been associated with QT interval prolongation, increasing the risk of life-threatening arrhythmias. A baseline electrocardiogram (ECG) is essential before initiating HCQ, with follow-up ECGs during treatment.

  • Patients with a corrected QT interval (QTc) ≥500 ms or those experiencing a >60 ms increase in QTc during treatment should discontinue HCQ.

3. Avoiding Drug Interactions:

  • Many drugs, including certain antibiotics (e.g., azithromycin) and antipsychotics, also prolong the QT interval. Concurrent use of such medications with HCQ should be avoided.

4. Electrolyte Monitoring:

  • Potassium, magnesium, and calcium levels should be maintained within normal ranges, as imbalances can exacerbate arrhythmias.

5. Diabetes Management:

  • HCQ can lower blood glucose, necessitating close monitoring in patients with diabetes to prevent hypoglycaemia.

Potential Benefits for Long COVID

HCQ’s ability to reduce inflammation and modulate immune responses may help address symptoms like fatigue and muscle pain, which are often linked to systemic inflammation. By stabilizing overactive immune pathways, HCQ could reduce the lingering effects of viral damage.

Limitations and Risks

Despite its potential, HCQ carries risks:

  • Ocular and Cardiac Toxicity: While short-term use poses minimal risk, long-term or high-dose use can cause retinal damage and exacerbate heart conditions.

  • Lack of Prophylactic Evidence: HCQ should not be used preventatively for COVID-19, as studies have not demonstrated efficacy in preventing infection or long COVID.

The Current Evidence and Future Directions

Although HCQ has shown mixed results in acute COVID-19 studies, its use in long COVID remains under-researched. Randomized controlled trials are needed to clarify its benefits, optimal dosing, and safety profile for long COVID patients. Until then, HCQ should be prescribed on a case-by-case basis, with comprehensive monitoring and an informed consent process outlining the risks and uncertainties.

Conclusion

HCQ offers a potential tool for managing certain symptoms of long COVID, particularly for patients with significant inflammation and immune dysregulation. However, its use must be balanced with careful risk assessment and ongoing monitoring to ensure safety. Patients interested in HCQ for long COVID should discuss the risks and benefits with their healthcare provider, ensuring all decisions are informed by the latest evidence.

As our understanding of long COVID evolves, so too will the role of treatments like HCQ, paving the way for more tailored and effective therapeutic options.

References:

Have questions about LDN or other treatments for Long COVID?
We’re here to help—reach out to Dr Finlays Long Covid clinic
for more information or to schedule a consultation. 

Learn About Our Services
>